1607. Clinical Outcomes at Month 6 after Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in an Observational Real-World Study (BEYOND)

Abstract Background CAB+RPV LA is the first complete long-acting regimen for virologically suppressed people with HIV (PWH) and demonstrated non-inferiority to standard of care antiretroviral regimens in the Phase 3/3b trials FLAIR, ATLAS, ATLAS-2M, and SOLAR. Implementation of a provider administer...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Open forum infectious diseases 2023-11, Vol.10 (Supplement_2)
Hauptverfasser:	Sinclair, Gary I, Sension, Michael, Dretler, Alexandra, Schneider, Stefan, Schubert, Catherine K, Merrill, Deanna, Richardson, David, Sherif, Bintu, Zografos, Laurie, Garris, Cindy
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!